Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 14

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis

Wijarnpreecha, Karn, Thongprayoon, Charat, Ungprasert, Patompong·2017·European Journal of Gastroenterology & Hepatology

Abstract

Background/objectives: Hepatitis C virus (HCV) infection is one of the most common causes of cirrhosis. Several studies have linked caffeine consumption to a lower degree of liver fibrosis and inflammation among patients with chronic HCV infection, but the results were inconsistent. This meta-analysis was carried out with the aim of assessing the impact of caffeine consumption among HCV-infected patients. Participants and methods: A literature search was performed using MEDLINE and EMBASE from inception to January 2016. Studies that reported relative risks, odd ratios, or hazard ratios comparing the risk of advanced liver fibrosis or the risk of moderate to severe liver inflammation among HCV-infected patients who consumed caffeine on a regular basis versus those who did not were included. Pooled odds ratios (OR) and 95% confidence interval (CI) were calculated using a random-effect, generic inverse-variance method. Results: Five studies were included in the fibrosis analysis. The pooled OR of advanced liver fibrosis in HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0.48 (95% CI, 0.30–0.76, I 2=52%). Three studies were included in the inflammation analysis. The pooled OR of moderate to severe histologic inflammation among HCV-infected patients who consumed caffeine on a regular basis versus those who did not was 0.61 (95% CI, 0.35–1.04, I 2=43%). Conclusion: Our study showed a decreased risk of advanced liver fibrosis and liver inflammation among HCV-infected patients who consumed caffeine on a regular basis. Whether consumption of caffeine plays a role in the management of HCV infection requires further investigations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/meg.0000000000000757

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 24

  1. Alter, 2007, Epidemiology of hepatitis C virus infection, World J Gastroenterol, 13, 2436, 10.3748/wjg.v13.i17.2436 · DOI · Paper page
  2. Denniston, 2014, Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010, Ann Intern Med, 160, 293, 10.7326/M13-1133 · DOI
  3. 2015, Hepatitis C guidance: AASLD–IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology, 62, 932, 10.1002/hep.27950 · DOI
  4. Storey, 2006, Beverage consumption in the US population, J Am Diet Assoc, 106, 1992, 10.1016/j.jada.2006.09.009 · DOI
  5. Zheng, 2014, Chlorogenic acid and caffeine in combination inhibit fat accumulation by regulating hepatic lipid metabolism-related enzymes in mice, Br J Nutr, 112, 1034, 10.1017/S0007114514001652 · DOI
  6. Costentin, 2011, Association of caffeine intake and histological features of chronic hepatitis C, J Hepatol, 54, 1123, 10.1016/j.jhep.2010.08.027 · DOI
  7. Khalaf, 2015, Coffee and caffeine are associated with decreased risk of advanced hepatic fibrosis among patients with hepatitis C, Clin Gastroenterol Hepatol, 13, 1521.e3, 10.1016/j.cgh.2015.01.030 · DOI
  8. Machado, 2014, Coffee has hepatoprotective benefits in Brazilian patients with chronic hepatitis C even in lower daily consumption than in American and European populations, Braz J Infect Dis, 18, 170, 10.1016/j.bjid.2013.09.001 · DOI
  9. Modi, 2010, Increased caffeine consumption is associated with reduced hepatic fibrosis, Hepatology, 51, 201, 10.1002/hep.23279 · DOI
  10. Oliveira Kda, 2015, Association of caffeine intake and liver fibrosis in patients with chronic hepatitis C, Arq Gastroenterol, 52, 4, 10.1590/S0004-28032015000100002 · DOI
  11. Stang, 2010, Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur J Epidemiol, 25, 603, 10.1007/s10654-010-9491-z · DOI · Paper page
  12. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  13. Higgins, 2003, Measuring inconsistency in meta-analyses, Bmj, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  14. Higgins, 2008, Induction of cancer chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. Evidence that the coffee-specific diterpenes cafestol and kahweol confer protection against acrolein, Toxicol Appl Pharmacol, 226, 328, 10.1016/j.taap.2007.09.018 · DOI
  15. Okano, 2008, Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway, Basic Clin Pharmacol Toxicol, 102, 543, 10.1111/j.1742-7843.2008.00231.x · DOI
  16. Abraham, 1999, Anti-genotoxicity and glutathione S-transferase activity in mice pretreated with caffeinated and decaffeinated coffee, Food Chem Toxicol, 37, 733, 10.1016/S0278-6915(99)00053-8 · DOI
  17. Gressner, 2008, Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways, J Hepatol, 49, 758, 10.1016/j.jhep.2008.03.029 · DOI
  18. Huber, 2008, Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver, Food Chem Toxicol, 46, 1230, 10.1016/j.fct.2007.09.094 · DOI
  19. McMahon, 2001, The Cap‘n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes, Cancer Res, 61, 3299
  20. Huber, 2002, Enhancement of the chemoprotective enzymes glucuronosyl transferase and glutathione transferase in specific organs of the rat by the coffee components kahweol and cafestol, Arch Toxicol, 76, 209, 10.1007/s00204-002-0322-1 · DOI
  21. Huber, 2002, The coffee components kahweol and cafestol induce gamma-glutamylcysteine synthetase, the rate limiting enzyme of chemoprotective glutathione synthesis, in several organs of the rat, Arch Toxicol, 75, 685, 10.1007/s00204-001-0295-5 · DOI
  22. Scharf, 2001, Elevation of glutathione levels by coffee components and its potential mechanisms, Adv Exp Med Biol, 500, 535, 10.1007/978-1-4615-0667-6_82 · DOI
  23. Tunnicliffe, 2008, Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators, Appl Physiol Nutr Metab, 33, 1290, 10.1139/H08-123 · DOI
  24. Ong, 2011, The effect of caffeine and alcohol consumption on liver fibrosis – a study of 1045 Asian hepatitis B patients using transient elastography, Liver Int, 31, 1047, 10.1111/j.1478-3231.2011.02555.x · DOI

Cited by

Metadata

Authors
Wijarnpreecha, K., Thongprayoon, C., & Ungprasert, P.
Affiliations
  • Department of Internal Medicine, Bassett Medical Center, Cooperstown, New York
  • Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA
Venue
European Journal of Gastroenterology & Hepatology
Published
2017-01
Volume
29
Issue
1
Pages
17-22
ISSN
0954-691X
Cited by
14
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.